ASSEMBLY BIOSCIENCES INC(NASDAQ:ASMB) stock News

ASMB Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: XTLB MCRB SNES SINT ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

a month ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

a month ago - By: Yahoo Finance - Mentions: GILD

Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

2 months ago - By: Yahoo Finance - Mentions: GILD

Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes

2 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

2 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

2 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

3 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

4 months ago - By: Zacks Investment Research - Mentions: TSHA

Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates

4 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

4 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

4 months ago - By: Zacks Investment Research - Mentions: AMPH

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates

4 months ago - By: Assembly Biosciences, Inc.

New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

4 months ago - By: Zacks Investment Research - Mentions: BBIO

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

5 months ago - By: Benzinga - Mentions: ADPT ICAD SYRA BCDA ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

5 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

5 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

6 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

6 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

6 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

6 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

7 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

8 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

8 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

9 months ago - By: Assembly Biosciences, Inc.

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

10 months ago - By: Assembly Biosciences, Inc.

ASSEMBLY BIOSCIENCES INC (ASMB) Stock News

ASMB Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Friday's After-Market Session

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Assembly Bio’s (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates

New Preclinical Data for Assembly Biosciences’ Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates